Subscribe
gavel_istock-517976804_avosb-
Avosb / iStockphoto.com
26 May 2017Americas

Biogen asks district court to dismiss competition complaint by Ixchel

Biogen has asked the US District Court for the Eastern District of California to dismiss a competition complaint filed by biotech company Ixchel Pharma.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Biogen to pay $1.25bn to Forward Pharma in licensing deal
19 January 2017   Biogen and Forward Pharma, a Denmark-based company, have entered into a settlement and licensing agreement under which Biogen will pay Forward Pharma $1.25 billion.
Americas
Biogen sues Teva over MS generic
18 March 2021   A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Biogen to pay $1.25bn to Forward Pharma in licensing deal
19 January 2017   Biogen and Forward Pharma, a Denmark-based company, have entered into a settlement and licensing agreement under which Biogen will pay Forward Pharma $1.25 billion.
Americas
Biogen sues Teva over MS generic
18 March 2021   A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.

More on this story

Americas
Biogen to pay $1.25bn to Forward Pharma in licensing deal
19 January 2017   Biogen and Forward Pharma, a Denmark-based company, have entered into a settlement and licensing agreement under which Biogen will pay Forward Pharma $1.25 billion.
Americas
Biogen sues Teva over MS generic
18 March 2021   A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent